Skip to main content
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Analysts’ Top Healthcare Picks: Centene (CNC), Eli Lilly & Co (LLY)

Tipranks - Tipranks - Wed Apr 1, 1:20PM CDT

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Centene (CNC), Eli Lilly & Co (LLY) and Gilead Sciences (GILD) with bullish sentiments.

End of Quarter Sale - 50% Off TipRanks

Centene (CNC)

Bernstein analyst Lance Wilkes maintained a Buy rating on Centene yesterday and set a price target of $48.00. The company’s shares closed last Tuesday at $32.44.

According to TipRanks.com, Wilkes ‘ ranking currently consits of 0 on a 0-5 ranking scale, with an average return of -8.7% and a 32.7% success rate. Wilkes covers the Healthcare sector, focusing on stocks such as Molina Healthcare, Elevance Health, and HCA Healthcare. ;'>

Currently, the analyst consensus on Centene is a Hold with an average price target of $42.29.

See Insiders’ Hot Stocks on TipRanks >>

Eli Lilly & Co (LLY)

Leerink Partners analyst David Risinger maintained a Buy rating on Eli Lilly & Co yesterday and set a price target of $1296.00. The company’s shares closed last Tuesday at $917.90.

According to TipRanks.com, Risinger is a top 100 analyst with an average return of 25.5% and a 62.2% success rate. Risinger covers the Healthcare sector, focusing on stocks such as Centessa Pharmaceuticals, XOMA Royalty Corporation, and Bristol-Myers Squibb. ;'>

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Eli Lilly & Co with a $1252.53 average price target, representing a 40.2% upside. In a report issued on March 20, TipRanks – xAI also upgraded the stock to Buy with a $1019.00 price target.

Gilead Sciences (GILD)

Bernstein analyst Courtney Breen maintained a Buy rating on Gilead Sciences yesterday and set a price target of $160.00. The company’s shares closed last Tuesday at $138.60.

According to TipRanks.com, Breen is a 4-star analyst with an average return of 19.4% and a 84.1% success rate. Breen covers the Healthcare sector, focusing on stocks such as Bristol-Myers Squibb, Merck & Company, and Eli Lilly & Co. ;'>

Gilead Sciences has an analyst consensus of Strong Buy, with a price target consensus of $159.39, which is a 16.2% upside from current levels. In a report issued on March 16, Cantor Fitzgerald also maintained a Buy rating on the stock with a $155.00 price target.

Read More on CNC:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).